CD4 and familial pancreatic carcinoma: The results reported in the previous study are consistent with our own findings (ORIVW=1.458, 95%CI=1.138–1.868) (Figure 3B), indicating that cortisone acts as a mediator, attenuating the impact of HLA DR+ CD4+ T lymphocytes on pancreatic cancer.